The European Monitoring Centre for Drugs and Drug Addiction (EMCDDA), which in 2024 will become the new European Drugs Agency with an expanded mandate, presented its annual report on Friday 16 June in which it expresses concern about the high availability of drugs and their “increased diversity”.
“Drug users are now exposed to a wider range of psychoactive substances, which are often of high potency and purity. As these substances can be sold in the form of powders or similar-looking...